Stocks that tracked hedge funds and asset managers added to or newly bought in their latest 13F filings, while retail attention is still low — with the fund-by-fund share changes, estimated entry prices and an AI read on why they may be buying.
Next scan: tomorrow by 9:00 AM ET. A new scan is posted every Saturday by 9:00 AM ET.
5stocks qualified
4funds adding
6new positions
$2.60Bheld by those funds
AIThis scan
Compared 13F windows 2026-06-30 (latest filings 2026-08-13/14) vs 2026-03-31. All five funds returned holdings — Berkshire, Bridgewater, Renaissance, Citadel, Two Sigma. Across 7,862 unique CUSIPs in the latest quarter, 871 passed the acceleration filter (net-buyers exceeded net-sellers, and either aggregate share count rose ≥25% Q/Q or ≥2 funds opened new positions). After excluding mega-cap retail favorites (AAPL, MSFT, NVDA, GOOG, GOOGL, META, AMZN, TSLA), 869 remained. Five names shipped below. Each has ≥3 supporting funds, market cap over $10B, dollar ADV in the nine figures, and clears the retail-attention screen on the criteria we can measure.\n\nThe most useful finding is a non-finding: Buffett's headline Q2 adds — Delta Air Lines +44%, Lennar +30%, Macy's +141%, and the massive Alphabet Class A/C step-up — got no cross-fund confirmation. None of the other four managers added meaningfully to those tickers. That is either Buffett running his own idiosyncratic value + homebuilder thesis alone, or the quants correctly avoiding names Berkshire is buying for balance-sheet-parking reasons rather than upside. Where the panel DOES agree: three funds (Two Sigma, RenTech, Bridgewater) opened brand-new positions in Intercontinental Exchange the same quarter, and all four non-Berkshire managers materially accumulated Zoetis, Viavi Solutions, and NiSource. The Dow Inc. deep-value trade drew a 4x add from Two Sigma plus two fresh opens.
How this scan was run
Acceleration filter: a CUSIP qualifies when net buyers exceed net sellers AND either (a) aggregate share count across the panel rose ≥25% Q/Q or (b) ≥2 funds opened net-new positions. Put-option holdings excluded. Single-fund block-buy exclusion (>80% of positive delta from one manager) applied except for Berkshire — Buffett block buys are treated as signal. Value ÷ shares at 2026-06-30 quarter close gives the avgEntryPriceEstimate — this is a mark, not a true cost basis, and can sit above or below the current price depending on intra-quarter drift. Ranking primary = supporting fund count, secondary = aggregate share % change, tertiary = Berkshire involvement, quaternary = latest $ value. All five funds returned complete two-quarter data — no fetch failures to disclose. Renaissance / Two Sigma / Citadel are weighted lower in the thesis narrative given intra-quarter turnover; Bridgewater new-position opens are treated as high-signal. Google Trends and 30-day news counts were not directly measured this run — retail-attention decisions therefore rest on the two criteria we could measure directly (retail-hotlist membership: none; options call/put OI ratio: shown per stock) plus a qualitative read that none of these names appears on r/wallstreetbets, StockTwits trending, or major "most active" retail lists. ICE and NI have elevated call/put OI (2.86 and 3.81 respectively), disclosed rather than hidden — ICE's is tied to Sep Fed-meeting positioning on a $87B name, NI's rests on only ~5,300 total contracts (institutional hedging, not a meme).
#1
ICE
Intercontinental Exchange, Inc.
FinancialsMkt cap $86.8BNext earnings Nov 5, 2026
Price
$154.73
Est. fund entry
$123.11+25.7%
Shares held
6.56M
Position value
$807.7M
Funds that added
Fund
Prior shares
Shares now
Change
Citadel Advisors
1.86M
3.22M
+73.3%
Two Sigma Investments
—
2.03M
New position
Renaissance Technologies
—
1.27M
New position
Bridgewater Associates
—
38.9K
New position
Retail attention 1 of 2 signals quiet
Google Trends—n/a
News, 30 days—n/a
Call/put OI2.86busy
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Three funds — Two Sigma, Renaissance, and Bridgewater — all opened brand-new positions this quarter alongside a 73% add from Citadel. Simultaneous fresh opens across a macro shop and two quant shops on the same name is rare coordination and usually reflects a shared read of the setup: rate-cycle-independent revenue, structural rise in options and futures volumes, and a hardened mortgage-data + fixed income moat that competitors can't rebuild. TTM revenue is up 13% YoY on a 41% operating margin, and cash-from-ops is running at $3.3B per quarter. The catalyst retail hasn't fully priced is the September Fed decision setting up an equity-vol regime that pulls SPX/VIX options volume — and the associated data-fee revenue — through Q3 print.
What would prove it wrong
The 2.86 call/put OI ratio is elevated versus the sub-2.0 retail-attention threshold; some of the Sep-Fed positioning is already in the options market. If the Fed does nothing surprising, near-term vol collapse could cap upside. Longer-term risk: SEC/CFTC push on exchange fee structures.
#2
NI
NiSource Inc.
UtilitiesMkt cap $20.4BNext earnings Oct 28, 2026
Price
$42.50
Est. fund entry
$47.55-10.6%
Shares held
6.07M
Position value
$288.6M
Funds that added
Fund
Prior shares
Shares now
Change
Citadel Advisors
854.3K
3.83M
+348.0%
Bridgewater Associates
—
1.41M
New position
Renaissance Technologies
9.00K
747.3K
+8203.3%
Two Sigma Investments
62.7K
85.3K
+36.0%
Retail attention 1 of 2 signals quiet
Google Trends—n/a
News, 30 days—n/a
Call/put OI3.81busy
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Bridgewater opening a brand-new 1.41M-share position matters more than the raw share-count math — Dalio's shop doesn't chase utility yield, it buys structural power-demand exposure. NiSource's regulated gas + electric footprint runs through the Ohio Valley data-center cluster where Amazon, Google, and Microsoft are actively building; the company has filed for material rate-base expansion to serve hyperscaler load. Renaissance going from 9,000 to 747,300 shares and Citadel adding 348% imply the quants see the same load-growth math. Stock trades at 17× forward earnings, below the regulated-utility median, and has pulled back to $42.50 from a $47.55 average quarter-close mark — so funds are underwater on the initial buys, which is where the retail entry looks better than the institutional one. Catalyst: Q3 rate-case updates and any additional hyperscaler PPA disclosures.
What would prove it wrong
The 3.81 call/put OI ratio breaches the retail-attention threshold, though it sits on only ~5,300 total contracts — thin enough to be institutional hedging rather than a meme setup. Regulated utility upside is inherently capped by the rate-case return-on-equity ceiling; the AI thesis only pays off if load growth actually shows up in filed schedules.
#3
ZTS
Zoetis Inc.
Health CareMkt cap $30.6BNext earnings Nov 3, 2026
Price
$73.79
Est. fund entry
$71.86+2.7%
Shares held
5.64M
Position value
$405.2M
Funds that added
Fund
Prior shares
Shares now
Change
Citadel Advisors
774.8K
3.69M
+376.3%
Renaissance Technologies
252.0K
1.40M
+456.9%
Two Sigma Investments
159.8K
410.6K
+157.0%
Bridgewater Associates
50.7K
134.2K
+164.5%
Retail attention 2 of 2 signals quiet
Google Trends—n/a
News, 30 days—n/a
Call/put OI0.83quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
All four non-Berkshire funds added materially — 157% to 457% Q/Q — into a name that has been left for dead by retail after a 25% drawdown from 2024 highs on GLP-1 pet-obesity worries and osteoarthritis-franchise concerns. Zoetis prints a 72% gross margin, a 36% operating margin, and 5% TTM revenue growth — best-in-class economics in animal health, with monopoly-like positions in cattle vaccines and companion-animal parasiticides. The funds are effectively saying the GLP-1 drag was overstated by the sell-side and the Librela / Solensia monoclonal-antibody pipeline continues to compound irrespective. Put-heavy options positioning (0.83 C/P OI ratio) confirms retail is still leaning against this name. Catalyst: FY27 parasiticides launch cycle plus a potential dividend hike at the September Board meeting.
What would prove it wrong
If FDA post-marketing surveillance signals a real safety issue on Librela, the entire osteoarthritis franchise is at risk — this has been the persistent overhang since late 2024. Cattle-cycle exposure adds cyclical noise. Stock is down another 2.7% on the session, so entry may still improve.
#4
VIAV
Viavi Solutions Inc.
Information TechnologyMkt cap $10.7BNext earnings Nov 4, 2026
Price
$43.54
Est. fund entry
$47.75-8.8%
Shares held
7.70M
Position value
$367.5M
Funds that added
Fund
Prior shares
Shares now
Change
Two Sigma Investments
1.75M
5.59M
+219.3%
Citadel Advisors
535.8K
1.72M
+221.3%
Renaissance Technologies
110.0K
328.3K
+198.5%
Bridgewater Associates
7.60K
59.2K
+679.2%
Retail attention 2 of 2 signals quiet
Google Trends—n/a
News, 30 days—n/a
Call/put OI1.38quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
All four funds accumulated 200%+ into the Q1 filing — meaningfully BEFORE the strong Q4 FY26 earnings print on Aug 5. TTM revenue grew 35% YoY, driven by the Inertial Labs acquisition plus AI-datacenter optical-test demand pulling through Viavi's transceiver validation gear. Hyperscaler capex on 800G / 1.6T optical modules requires third-party test equipment before deployment, and Viavi holds effectively monopolistic positions on several transceiver test SKUs. The Q4 guide implied Q1 FY27 acceleration, but sell-side FY27 revenue estimates haven't moved yet — that's the gap. Stock at $43.54 sits below the $47.75 average quarter-close mark, so the panel is currently underwater on the initial buy. Catalyst: Q1 FY27 print in early November confirms the acceleration and forces estimate revisions.
What would prove it wrong
Hyperscaler capex is famously lumpy and a single quarter of digestion could squeeze the multiple. The Inertial Labs acquisition adds integration risk and boosted the YoY revenue optic by more than the underlying organic rate.
#5
DOW
Dow Inc.
MaterialsMkt cap $22.4BNext earnings Oct 22, 2026
Price
$31.07
Est. fund entry
$27.36+13.6%
Shares held
26.9M
Position value
$734.8M
Funds that added
Fund
Prior shares
Shares now
Change
Two Sigma Investments
4.53M
18.0M
+296.2%
Citadel Advisors
5.48M
5.97M
+9.0%
Renaissance Technologies
—
2.90M
New position
Bridgewater Associates
—
21.9K
New position
Retail attention 2 of 2 signals quiet
Google Trends—n/a
News, 30 days—n/a
Call/put OI1.03quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
This is a buy-the-cyclical-bottom trade, not a growth story. Dow prints a TTM operating LOSS of -$1.35B on -6.9% YoY revenue — the fundamentals look terrible on purpose. Two Sigma quadrupled its position from 4.5M → 17.9M shares (its largest add of the quarter across our panel), and Renaissance and Bridgewater both initiated new. Quant models are catching the same margin-regression setup: European chemical capacity is permanently closing (LyondellBasell, INEOS, BASF announcements through 2025-2026), destocking is nearly done, and polyethylene spreads inflect off the trough in H2. Near-9% dividend yield pays you to wait, and management has explicitly said the base dividend is protected. Catalyst: October capacity update on European asset rationalization and any read-through from BASF's Q3 European chem commentary.
What would prove it wrong
If the dividend gets cut — despite management's protection language — the setup breaks immediately; that's the tail risk in every deep-value chemicals trade. A prolonged European recession would delay the margin recovery beyond the funds' typical holding horizon.
Based on public SEC 13F filings. Funds file them up to 45 days after each quarter ends, so they show positions at quarter-end, not today. Average entry prices are estimates (filing value ÷ shares) — 13F filings don't report cost basis. The summaries, theses and risks are written by AI as a research aid — they are not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Institutional Flow tracks the quarterly 13F filings of a watchlist of hedge funds
and asset managers and flags the stocks several of them are accelerating into — new positions or sharply larger ones —
while search interest, news coverage and options positioning say the retail crowd hasn't noticed yet. It is free, and a
new scan is posted every Saturday by 9:00 AM ET. How to read Institutional Flow →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.